News|Articles|May 15, 2020
- Pharmaceutical Technology-05-15-2020
- Volume 2020 eBook
- Issue 2
On Point: Biologics Drive Growth in Pre-Filled Syringes
Author(s)Felicity Thomas
As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.
Advertisement
With an aging population, the resultant increase in prevalence of chronic diseases, and more demand from patients for dosing convenience, the biopharma industry has seen an exponential increase in adoption of biological therapies delivered in prefilled syringes. The overall prefilled syringes market is forecasted to be worth nearly $10 billion by the year 2025, according to market research (1), driven in part by the rise in use of biological drugs. This article discusses the challenges, safety considerations, and emerging trends in the field of pre-filled syringes for biologics.
Article Details
Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing, May 2020
May 2020
Pages: 20–23
Citation
When referring to this article, please cite it as F. Thomas, "On Point: Biologics Drive Growth in Pre-Filled Syringes," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2020).
Articles in this issue
over 5 years ago
Instrumenting Single-Use Processesover 5 years ago
Considerations in Contamination Controlover 5 years ago
Best systems and equipment for contamination controlover 5 years ago
Building Data Quality In Generates Quality Data Outover 5 years ago
Detecting Contamination in Cell Therapiesover 5 years ago
Optimizing Viral Vector Manufacturing for Gene Therapyover 5 years ago
Minimizing Contamination During Biopharma R&Dover 5 years ago
Complications in Process Simulation ExecutionNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
